CN106459201A - 结合人和食蟹猴CD3ε的抗体 - Google Patents

结合人和食蟹猴CD3ε的抗体 Download PDF

Info

Publication number
CN106459201A
CN106459201A CN201580026998.5A CN201580026998A CN106459201A CN 106459201 A CN106459201 A CN 106459201A CN 201580026998 A CN201580026998 A CN 201580026998A CN 106459201 A CN106459201 A CN 106459201A
Authority
CN
China
Prior art keywords
human
antibody
cells
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580026998.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·蒂芬塔勒
E·默斯纳
V·利夫克
J·普拉策
S·奥夫纳
C·耶格
M·里特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106459201A publication Critical patent/CN106459201A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580026998.5A 2014-05-28 2015-05-22 结合人和食蟹猴CD3ε的抗体 Pending CN106459201A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14170140.9 2014-05-28
EP14170140 2014-05-28
EP14180572.1 2014-08-11
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (1)

Publication Number Publication Date
CN106459201A true CN106459201A (zh) 2017-02-22

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580026998.5A Pending CN106459201A (zh) 2014-05-28 2015-05-22 结合人和食蟹猴CD3ε的抗体

Country Status (13)

Country Link
US (3) US20170233475A1 (enExample)
EP (2) EP3763739A1 (enExample)
JP (1) JP6738285B2 (enExample)
KR (1) KR20170003591A (enExample)
CN (1) CN106459201A (enExample)
AU (1) AU2015266077A1 (enExample)
BR (1) BR112016022819A2 (enExample)
CA (1) CA2942453A1 (enExample)
IL (1) IL247740A0 (enExample)
MX (1) MX2016015389A (enExample)
RU (1) RU2016151235A (enExample)
SG (1) SG11201609950YA (enExample)
WO (1) WO2015181098A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111417719A (zh) * 2017-11-30 2020-07-14 豪夫迈·罗氏有限公司 B细胞培养方法
WO2023273762A1 (zh) * 2021-06-30 2023-01-05 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN118126180A (zh) * 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
JP2020521791A (ja) 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US11319371B2 (en) 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
CN111108119B (zh) * 2017-09-21 2022-11-15 上海药明生物技术有限公司 新型抗CD3ε抗体
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
PE20230389A1 (es) * 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
JP7851303B2 (ja) * 2020-09-24 2026-04-24 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒトｃｄ３イプシロンに結合する新規なヒト抗体
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
WO2023183766A1 (en) * 2022-03-20 2023-09-28 Abcellera Biologics Inc. Anti-cd3 antibodies and t-cell engagers and methods of use
JP2025513714A (ja) * 2022-03-22 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃｄ３に特異的な脱免疫抗体
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
SI2155788T1 (sl) * 2007-04-03 2012-11-30 Amgen Res Munich Gmbh Bispecifični vezavni element specifičen za križane vrste
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111417719A (zh) * 2017-11-30 2020-07-14 豪夫迈·罗氏有限公司 B细胞培养方法
CN111417719B (zh) * 2017-11-30 2023-08-29 豪夫迈·罗氏有限公司 B细胞培养方法
WO2023273762A1 (zh) * 2021-06-30 2023-01-05 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用

Also Published As

Publication number Publication date
US20200325224A1 (en) 2020-10-15
BR112016022819A2 (pt) 2018-01-16
MX2016015389A (es) 2017-04-13
US20200299385A1 (en) 2020-09-24
EP3149041A1 (en) 2017-04-05
RU2016151235A (ru) 2018-06-28
SG11201609950YA (en) 2016-12-29
AU2015266077A1 (en) 2016-09-29
JP2017516786A (ja) 2017-06-22
CA2942453A1 (en) 2015-12-03
IL247740A0 (en) 2016-11-30
KR20170003591A (ko) 2017-01-09
RU2016151235A3 (enExample) 2019-01-18
WO2015181098A1 (en) 2015-12-03
JP6738285B2 (ja) 2020-08-12
US20170233475A1 (en) 2017-08-17
EP3763739A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
US20230279109A1 (en) Anti-tim3 antibodies and methods of use
US20200299385A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
JP7592050B2 (ja) 抗ｈｌａ－ｇ抗体とその使用
US20250051456A1 (en) Anti-hla-g antibodies and methods of use thereof
CN108368173B (zh) 抗pd1抗体及使用方法
JP2019500853A (ja) 抗ｔｐｂｇ抗体と使用方法
HK1231092A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
HK40011622B (en) Anti-hla-g antibodies and use thereof
HK1259019B (en) Anti-pd1 antibodies and methods of use
HK1241906B (en) Anti-tim3 antibodies and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231092

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20210730

AD01 Patent right deemed abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231092

Country of ref document: HK